×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
OTCMKTS:HLUYY

H. Lundbeck A/S (HLUYY) Stock Forecast, Price & News

$24.02
+1.35 (+5.96%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.02
$24.02
50-Day Range
$21.06
$24.60
52-Week Range
$21.06
$32.52
Volume
750 shs
Average Volume
1,171 shs
Market Capitalization
$4.78 billion
P/E Ratio
14.65
Dividend Yield
0.88%
Beta
0.6
30 days | 90 days | 365 days | Advanced Chart
Receive HLUYY News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

H. Lundbeck A/S logo

About H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HLUYY
CIK
N/A
Employees
5,348
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.59 billion
Cash Flow
$2.36 per share
Book Value
$14.60 per share

Profitability

Net Income
$209.69 million
Pretax Margin
9.70%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$4.78 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2015
Ex-Dividend for 4/5 Dividend
3/24/2022
Dividend Payable
4/05/2022
Today
5/29/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Analyst Opinion: 3.0Community Rank: 4.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













H. Lundbeck A/S (OTCMKTS:HLUYY) Frequently Asked Questions

Is H. Lundbeck A/S a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last twelve months. There are currently 2 sell ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" H. Lundbeck A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLUYY, but not buy additional shares or sell existing shares.
View analyst ratings for H. Lundbeck A/S
or view top-rated stocks.

Are investors shorting H. Lundbeck A/S?

H. Lundbeck A/S saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 8,300 shares, an increase of 232.0% from the April 30th total of 2,500 shares. Based on an average trading volume of 1,900 shares, the short-interest ratio is currently 4.4 days.
View H. Lundbeck A/S's Short Interest
.

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) issued its quarterly earnings results on Wednesday, November, 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.16. The company earned $547.05 million during the quarter, compared to the consensus estimate of $514.82 million. H. Lundbeck A/S had a net margin of 8.09% and a trailing twelve-month return on equity of 10.37%.
View H. Lundbeck A/S's earnings history
.

How often does H. Lundbeck A/S pay dividends? What is the dividend yield for H. Lundbeck A/S?

H. Lundbeck A/S declared a dividend on Saturday, March 19th. Shareholders of record on Friday, March 25th will be given a dividend of $0.2044 per share on Tuesday, April 5th. This represents a yield of 0.85%. The ex-dividend date of this dividend is Thursday, March 24th.
View H. Lundbeck A/S's dividend history
.

Is H. Lundbeck A/S a good dividend stock?

H. Lundbeck A/S pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.88%. The dividend payout ratio of H. Lundbeck A/S is 12.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, H. Lundbeck A/S will have a dividend payout ratio of 7.04% next year. This indicates that H. Lundbeck A/S will be able to sustain or increase its dividend.
View H. Lundbeck A/S's dividend history.

What price target have analysts set for HLUYY?

4 Wall Street analysts have issued 1-year price targets for H. Lundbeck A/S's stock. Their forecasts range from $30.67 to $200.00. On average, they expect H. Lundbeck A/S's stock price to reach $145.92 in the next year. This suggests a possible upside of 507.5% from the stock's current price.
View analysts' price targets for H. Lundbeck A/S
or view top-rated stocks among Wall Street analysts.

Who are H. Lundbeck A/S's key executives?
H. Lundbeck A/S's management team includes the following people:
  • Dr. Deborah Dunsire M.D., Pres & CEO (Age 60, Pay $7.59M)
  • Mr. Jacob Tolstrup, Exec. VP of Commercial Operations & Chief Commercial Officer (Age 50, Pay $942.08k)
  • Mr. Lars Bang, Exec. VP of Product Devel. & Supply (Age 60, Pay $971.07k)
  • Dr. Per Johan Luthman, Exec. VP of R&D (Age 63, Pay $956.58k)
  • Dr. Tarek Samad Ph.D., Sr. VP & Head of Research
  • Mr. Palle Holm Olesen, Chief Specialist & VP of Investor Relations
  • Ms. Elise Hauge, Exec. VP of People & Communication (Age 55)
  • Mr. Ole Chrintz, Sr. VP of International Markets (Age 64)
  • Mr. Keld Flintholm Jorgensen, Exec. VP of Corp. Strategy & Bus. Devel. (Age 51)
  • Dr. Rupert Sandbrink M.D., Ph.D., Sr. VP & Head of Clinical Devel. (Age 58)
What is H. Lundbeck A/S's stock symbol?

H. Lundbeck A/S trades on the OTCMKTS under the ticker symbol "HLUYY."

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is H. Lundbeck A/S's stock price today?

One share of HLUYY stock can currently be purchased for approximately $24.02.

How much money does H. Lundbeck A/S make?

H. Lundbeck A/S has a market capitalization of $4.78 billion and generates $2.59 billion in revenue each year. The company earns $209.69 million in net income (profit) each year or $1.639990 on an earnings per share basis.

How many employees does H. Lundbeck A/S have?

H. Lundbeck A/S employs 5,348 workers across the globe.

What is H. Lundbeck A/S's official website?

The official website for H. Lundbeck A/S is www.lundbeck.com.

How can I contact H. Lundbeck A/S?

H. Lundbeck A/S's mailing address is Ottiliavej 9 Valby, Copenhagen G7, 2500. The company can be reached via phone at (453) 630-1311, via email at [email protected], or via fax at 45-3630-1940.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.